Retatrutide
Also known as: LY3437943, RETA, Triple G
Source Retatrutide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Retatrutide is a novel triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, developed for obesity and type 2 diabetes with superior weight loss efficacy in Phase 2 trials
Mechanism of Action
Activates GLP-1, GIP, and glucagon receptors to enhance insulin secretion, suppress appetite, increase energy expenditure, and promote weight loss
Routes of Administration
Goals & Uses
- NAFLD/NASH treatmentHepaticModerate
- Cardiovascular risk reductionCardiovascularModerate
- Weight lossMetabolicHighChronic weight management and appetite reduction
- Glycemic controlDiabetesHigh
Contraindications
- personal/family history of medullary thyroid carcinomaOncologicHigh
- Multiple endocrine neoplasia syndrome type 2OncologyHighClass-related warning for selected incretin therapies
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- increased heart rateCardiovascularCommon
- Injection site reactionsLocalUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- gallbladder-related disordersHepatobiliaryUncommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
Drug Interactions
- Oral contraceptivesLowDelayed gastric emptying may affect absorption timing
- WarfarinModerate
- insulin secretagoguesModerate
Population Constraints
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- History of pancreatitisGastrointestinalRelative
- diabetic retinopathyOphthalmologicRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalEMA parallel scientific advice obtained
- United StatesInvestigationalFast Track designation for obesity; Phase 3 SURMOUNT and SURPASS programs ongoing
- United KingdomInvestigationalPart of global Phase 3 development program
Fast Track designation granted by FDA for obesity treatment; Phase 3 trials ongoing as of 2024
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Retatrutide?
Retatrutide is a novel triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, developed for obesity and type 2 diabetes with superior weight loss efficacy in Phase 2 trials
What is Retatrutide used for?
Retatrutide is educationally associated with: NAFLD/NASH treatment, Cardiovascular risk reduction, Weight loss, Glycemic control. Educational only — not medical advice.
How is Retatrutide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Retatrutide?
Reported adverse effects include: increased heart rate, Injection site reactions, Nausea, Vomiting, gallbladder-related disorders, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Retatrutide?
Recorded contraindications: personal/family history of medullary thyroid carcinoma, Multiple endocrine neoplasia syndrome type 2, Pregnancy. Consult a qualified clinician before use.